PCN216 - Treatment Pattern And Direct Medical Costs Among Patients With Lung Cancer In China

Abstract

Listen

Translate article

To explore the treatment pattern and to estimate direct medical costs in lung cancer patients. A retrospective observational study was carried out on the basis of China Health Insurance Research Association (CHIRA) database in 2016. Patients with ≥1 diagnosis of lung cancer during the first season were identified. If the patient met one of the following criteria: 1) with other cancer diagnosis; 2) complicated with schizophrenia; 3) receiving hemodialysis or peritoneal dialysis treatment, he (she) would be excluded. Eligible patients were classified into one of the subgroups by the treatment methods: 1) chemotherapy group; 2) radiotherapy group; 3) radiotherapy combined with chemotherapy group; 4) surgical treatment group; 5) targeted agent group; 6) palliative treatment group. The age, sex, proportion and annual direct medical costs of those subgroups were described and calculated. 3,365 lung cancer patients met the inclusion criteria. The mean age was 65.2±11.0 years. 65.1% of the total participants were male. The proportion of the chemotherapy group, radiotherapy group, radiotherapy combined with chemotherapy group, surgical treatment group, targeted agent group and palliative treatment group was 20.5% (n=691), 6.2% (n=210), 10.4% (n=350), 4.7% (n=157), 2.9% (n=96) and 55.3% (n=1,861), respectively. The annual mean all-cause direct medical cost per capita was CNY 53,143.8±60,771.3. The ratio of the cost covered by medical insurance reimbursement was 71.8%. Medication cost made up 55.6% of the total cost. The annual mean all-cause direct medical cost per capita of the subgroups above was CNY 61,253.0±58,682.3, CNY 63,266.5±51,248. 7, CNY 113,001.5±66,705.1, CNY 100,338.3±4,8949.3, CNY 161,089.4±90,240.3 and CNY 28,183.2±39,141.9, respectively. The percentage of the medication cost was the highest in the targeted agent group (CNY 104,534.5±67,592.3, 64.9%). In this database analysis, more than half of the lung cancer patients received palliative treatment. The total annual direct medical cost was the highest in patients who received targeted agent treatment.